Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib
- S. Ferreira, E. Guttman‐Yassky, T. Torres
- Biology, MedicineAmerican Journal of Clinical Dermatology
- 10 August 2020
Data from phase II and III trials are encouraging, revealing that JAK1 inhibitors are effective and well-tolerated agents for moderate-to-severe atopic dermatitis.
JAK/STAT inhibitors for the treatment of atopic dermatitis
JAK inhibitors will most certainly be the first oral targeted option when topical therapy fails, and less clear is the position in the therapeutic ladder for topical JAK inhibitors; although, an unmeet need exists in the topical treatment of AD.
JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
Current data on the impact of JAK inhibitors in the treatment of adult patients with moderate-to-severe psoriasis is reviewed.
Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study
The Protective Role of HLA-DRB1∗13 in Autoimmune Diseases
- A. Bettencourt, C. Carvalho, B. M. da Silva
- Biology, MedicineJournal of Immunological Research
- 29 October 2015
Although different alleles were associated with particular AIDs, the same allele, HLA-DRB1∗13, was underrepresented in all of the six diseases analysed, suggesting that this allele may confer protection for AID, particularly for systemic and rheumatic disease.
Palmoplantar Psoriasis and Palmoplantar Pustulosis: Current Treatment and Future Prospects
Knowledge of the pathophysiologic pathways of both entities is of utmost importance and may, in the future, allow development of molecularly targeted therapeutics.
No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents
- A. Chiricozzi, M. Romanelli, R. Saraceno, T. Torres
- PsychologyExpert Opinion on Drug Safety
- 31 August 2016
This review sought to provide an overview strictly focused on suicide behavior signals related to the use of IL-17 agents, suggesting that cases of suicidal behavior accidentally occurred during brodalumab trials.
Aprepitant: Evidence of its effectiveness in patients with refractory pruritus continues.
Risk of tuberculosis reactivation with interleukin (IL)‐17 and IL‐23 inhibitors in psoriasis – time for a paradigm change
- M. Nogueira, R. Warren, T. Torres
- Medicine, BiologyJournal of the European Academy of Dermatology…
- 12 August 2020
The emergence of new biological drugs for the treatment of psoriasis, such as interleukin (IL)‐17 and IL‐23 inhibitors, has reignited the subject of tuberculosis reactivation, and its possible impact on the way the authors currently manage latent tuberculosis infection before or after starting treatment with these new drugs is reviewed.
Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to ustekinumab
The main susceptibility gene in psoriasis, HLACw*0602 polymorphism, is the main genetic risk factor for the disease and its expression is generally linked to an early onset, longer duration, and severity of the disease.